Julia Belluz

speaker

540 appearances 2 recordings 2 series first heard Feb 2026 last heard 8 May

Julia Belluz’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 2 in all, peaking in May 2026 with 1.

Appearances

newest first · ▶ plays the moment

The Ezra Klein Show · GLP-1s and the ‘Wild West’ of Wellness · 8 May 2026 podcast

So the Alzheimer's trials, so these were really much anticipated, randomized controlled trials to see what would happen with these drugs and Alzheimer's, and they had negative results.

And so it was a big disappointment to the community and to the companies.

But there is this question of in a different population or with a different dose or a different drug, will we see the benefits?

And that's an active question.

Yeah, if you're intervening earlier, it's an active question and area of study.

So I don't think that case is closed.

And sleep apnea is a big one.

Sleep apnea is weight dependent.

So you need to lose the weight to see the benefit.

But that's another indication that these drugs are approved for now.

So there's a researcher in Toronto, Dan Drucker, who helped discover this whole class of drugs.

And he described to me, like, basically there's these three buckets.

So one is the weight loss bucket.

That's clear.

It's going to help you lose weight and you'll get the benefits from the weight loss.

The second bucket is reducing inflammation.

So inflammation is when you're exposed to a pathogen, an infection, an injury, your body mounts this immune response and it can signal healing.

But when it goes into kind of overdrive at low levels, you have this chronic inflammation.

And that's a hallmark of many of these diseases we've been talking about, obesity, diabetes, cardiovascular disease.

And these drugs seem to work on inflammation.

Showing 181–200 of 540 · page 10 of 27